Cancer immunotherapy has transformed the treatment landscape for many advanced cancers over the past decade. Drugs targeting the PD-1 and PD-L1 pathways are now widely used across several tumor types, helping the immune system recognize and attack cancer cells more effectively. However, researchers are still working to understand how beneficial these therapies may be when used earlier in the disease course, particularly after surgery in patients with high-risk solid tumors.

A research paper on this topic was published in Volume 17 of Oncotarget titled “Efficacy and safety of PD-1/ PD-L1 inhibitors as adjuvants in the treatment of patients with solid cancers: A systematic review and meta-analysis of randomized controlled trials.”

Full blog - https://www.oncotarget.org/2026/05/20/immune-checkpoint-inhibitors-may-improve-outcomes-in-high-risk-solid-tumors/

Paper DOI - https://doi.org/10.18632/oncotarget.28855

Correspondence to - Dhai Almuteri - [email protected]

Abstract video - https://www.youtube.com/watch?v=4Ce07bHfjB4

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28855

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, PD-1, PD-L1, adjuvant immunotherapy, solid tumor

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/

X - https://twitter.com/oncotarget

Instagram - https://www.instagram.com/oncotargetjrnl/

YouTube - https://www.youtube.com/@OncotargetJournal

LinkedIn - https://www.linkedin.com/company/oncotarget

Pinterest - https://www.pinterest.com/oncotarget/

Reddit - https://www.reddit.com/user/Oncotarget/

Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh